The efficacy and safety of ixekizumab, adalimumab, and placebo in patients with psoriatic arthritis naive to biological disease-modifying anti-rheumatic drugs: a double-blind phase 3 study

被引：0
|
作者：
Mease, P. [1 ]
van der Heijde, D. [2 ]
Ritchlin, C. [3 ]
Cuchacovich, R. [4 ,5 ]
Shuler, C. [4 ]
Lin, C-Y [4 ]
Vangerow, H. [4 ]
Samanta, S. [4 ]
Lee, C. H. [4 ]
Gladman, D. [6 ]
Larsson, E. [7 ]
机构：
[1] Dept Rheumatol, Rochester, MN USA
[2] Leiden Univ, Med Ctr, NL-2300 RA Leiden, Netherlands
[3] Univ Rochester, Allergy Immunol & Rheumatol Div, Rochester, NY 14627 USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[6] Univ Toronto, Dept Med, Div Rheumatol, Toronto, ON M5S 1A1, Canada
[7] Eli Lilly Sweden AB, Solna, Sweden
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2016年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP38
引用
收藏
页码：31 / 33
页数：3
相关论文
共 50 条
  • [1] A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis
    Mease, Philip J.
    van der Heijde, Desiree
    Ritchlin, Christopher T.
    Cuchacovich, Raquel
    Shuler, Catherine L.
    Lee, Chin H.
    Samanta, Suvajit
    Lin, Chen-Yen
    Gladman, Dafna D.
    Vangerow, Harald
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [2] A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease-modifying antirheumatic drugs with active psoriatic arthritis
    Mease, P. J.
    van der Heijde, D.
    Ritchlin, C. T.
    Cuchacovich, R. S.
    Shuler, C. L.
    Lin, C.
    Vangerow, H.
    Samanta, S.
    Lee, C. H.
    Gladman, D. D.
    [J]. EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E30 - E30
  • [3] Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
    McInnes, Iain
    Anderson, Jaclyn K.
    Magrey, Marina
    Merola, Joseph
    Liu, Yi
    Kishimoto, Mitsumasa
    Jeka, Slawomir
    Tena, Cesar Pacheco
    Wang, Xin
    Chen, Liang
    Zueger, Patrick
    Pangan, Aileen
    Behrens, Frank
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [4] A Randomized, Double-blind, Active-and Placebo-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Antirheumatic Drugs with Active Psoriatic Arthritis
    Mease, Philip
    van der Heijde, Desiree
    Ritchlin, Christopher
    Cuchacovich, Raquel
    Shuler, Catherine
    Lin, Chen-Yen
    Vangerow, Harald
    Samanta, Suvajit
    Lee, Chin
    Gladman, Dafna
    [J]. JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1169 - 1169
  • [5] Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
    Genovese, Mark
    Lertratanakul, Apinya
    Anderson, Jaclyn K.
    Papp, Kim
    Tillett, William
    Van den Bosch, Filip
    Tsuji, Shigeyoshi
    Dokoupilova, Eva
    Keiserman, Mauro
    Wang, Xin
    Zhong, Sheng
    Zueger, Patrick
    Pangan, Aileen
    Mease, Philip
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [6] A randomized, double-blind, active-and placebo (PBO)-controlled phase 3 study of efficacy and safety of ixekizumab (IXE), adalimumab (ADA), and placebo therapy in patients naive to biologic disease-modifying antirheumatic drugs (bDMARDs) with active psoriatic arthritis (PsA)
    Burkhardt, N.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 40 - 40
  • [7] A Randomized, Double-blind, Active-and Placebo (PBO)-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab (IXE), Adalimumab (ADA), and Placebo Therapy in Patients Naive to Biologic Disease-modifying Antirheumatic Drugs (bDMARDs) with Active Psoriatic Arthritis (PsA)
    Mease, P.
    van der Heijde, D.
    Ritchlin, C.
    Cuchacovich, R.
    Shuler, C.
    Lin, C-Y
    Vangerow, H.
    Samanta, S.
    Lee, C.
    Gladman, D.
    Magloire, A.
    [J]. SWISS MEDICAL WEEKLY, 2016, 146 : 6S - 6S
  • [8] EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
    Mcinnes, I.
    Anderson, J.
    Magrey, M.
    Merola, J. F.
    Liu, Y.
    Kishimoto, M.
    Jeka, S.
    Tena, C. F. Pacheco
    Wang, X.
    Chen, L.
    Zueger, P.
    Pangan, A.
    Behrens, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 12 - 13
  • [9] A Randomized, Double-blind, Active- and Placebo (PBO)-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab (IXE), Adalimumab (ADA), and Placebo Therapy in Patients Naive to Biologic Disease modifying Antirheumatic Drugs (bDMARDs) with Active Psoriatic Arthritis (PsA)
    Mease, P. J.
    Eppendorfer, S.
    van der Heijde, D.
    Ritchlin, C. T.
    Cuchacovich, R. S.
    Shuler, C. L.
    Lin, C. -Y.
    Vangerow, H.
    Samanta, S.
    Lee, C. H.
    Gladman, D. D.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 5 - 5
  • [10] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
    Genovese, M. C.
    Lertratanakul, A.
    Anderson, J.
    Papp, K.
    Tillett, W.
    Van den Bosch, F.
    Tsuji, S.
    Dokoupilova, E.
    Keiserman, M.
    Wang, X.
    Zhong, S.
    Zueger, P.
    Pangan, A.
    Mease, P. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 139 - 139
12345